SOUTH SAN FRANCISCO (dpa-AFX) – The European Commission approved Roche’s (RHHBY) Evrysdi or risdiplam for babies under two months old with spinal muscular atrophy, the company said in a statement. The Evrysdi is now available to treat people of all ages with spinal muscular atrophy in the European Union, including…Read More
EU Okays Roches Evrysdi For Babies Under Two Months Old With Spinal Muscular Atrophy
